Entering text into the input field will update the search result below

FDA appears positive about Kythera’s double-chin injection

Mar. 05, 2015 8:28 AM ETKYTHERA Biopharmaceuticals (KYTH) StockKYTHBy: Eli Hoffmann, SA News Editor3 Comments
  • FDA says data present "a consistent and favorable safety profile for ATX-101."
  • FDA advisory panel to meet the morning of March 9 to discuss Kythera's (NASDAQ:KYTH) application seeking approval for ATX-101 to treat double chin. It would be the first drug to treat double chin.
  • Annual sales of ATX-101 may reach $510M by 2020.
  • Shares +4.2% premarket.
  • Link: FDA brief

Recommended For You

Related Stocks

SymbolLast Price% Chg
KYTH--
KYTHERA Biopharmaceuticals
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.